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3Department of Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 4 Institute for Medicine of Chronic Disease, Disease
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Background. CCN family, comprising six members (Cyr61, CTGF, Nov, WISP-1, WISP-2, WISP-3), is involved in the stimulation of
cell proliferation, migration, adhesion, angiogenesis, and tumorigenesis. Several studies have shown that expression of Cyr61,
CTGF, and WISP-1 affects the tumorigenic potential of lung cancer cells in vitro. However, the correlation of expression of CCN
family proteins and clinical features of lung cancer remains unknown. Methodology and Principal Findings. In the present
work, we quantified the mRNA levels of Cyr61, CTGF, and WISP-1 in samples from 60 primary lung cancers and their matched
normal lung tissues by quantitative real-time PCR assay. Downregulation of the Cyr61 and CTGF genes and upregulation of the
WISP-1 gene were found in primary lung cancers compared to the paired normal lung tissues. Immunohistochemistry analysis also
disclosed a similar expression pattern of Cyr61, CTGF, andWISP-1 protein in paired lung cancer tissues. Statistical analysis revealed
significant associations between expression of either Cyr61 or CTGF with tumor stage, tumor histology, metastasis, smoking, and
family history at diagnosis. A significant correlation also existed betweenWISP-1 expressionwith tumor histology, and patient age.
Moreover, expression levels of Cyr61 and CTGF correlated with survival of the lung-cancer patients. Conclusions. Our results
suggest that Cyr61, CTGF, and WISP-1 might be implicated in the development and progression of primary lung cancers, and their
levels might serve as valuable prognostic markers, as well as potential targets for therapeutic intervention.
Citation: Chen P-P, Li W-J, Wang Y, Zhao S, Li D-Y, et al (2007) Expression of Cyr61, CTGF, and WISP-1 Correlates with Clinical Features of Lung
Cancer. PLoS ONE 2(6): e534. doi:10.1371/journal.pone.0000534
INTRODUCTION
Lung cancer is the most common cause of cancer death in the
world [1]. The majority of lung cancers are non-small-cell lung
carcinoma (NSCLC), which is subdivided into adenocarcinoma
(AC), squamous-cell carcinoma (SC), and large-cell carcinoma [2].
The high mortality associated with NSCLC is in part due to
metastasis before surgical removal of the primary tumor. Tumor
metastasis involves detachment of tumor cells from the primary
tumor mass, microinvasion of tumor cells into stromal tissue,
intravasation of tumor cells into blood vessels, and extravasation
and growth of tumor cells in secondary sites [3,4]. To become
metastatic, tumor cells must increase the expression of metastasis-
promoting genes and/or decrease the expression of metastasis-
suppressing genes. Utilizing human lung cancer cell lines, cysteine-
rich protein 61 (Cyr61) and connective tissue growth factor
(CTGF) have been demonstrated to inhibit metastasis and
invasion of cancer cells, and therefore they have been considered
as potential suppressors of metastasis [5,6].
Both CTGF and Cyr61 belong to the CCN family, named for
its three first described members - Cyr61 (CCN1), CTGF (CCN2),
and Nov (nephroblastoma overexpressed, CCN3) [7]. CCN family
has six members : Cyr61, CTGF, Nov, WISP-1 (Wnt-1-induced
secreted protein 1) (CCN4), WISP-2 (CCN5) and WISP-3 (CCN6)
[8–11]. These proteins are modular in structure, consisting of an
N-terminal signal sequence followed by domains with sequence
similarity to insulin-like growth factor-binding protein, von
Willebrand factor C, thrombospondin type 1, and a cysteine knot
at the C terminus with an exception of WISP-2, which lacks the C
terminus region [12]. All CCN molecules are secreted, extracel-
lular matrix-associated proteins and involved in internal and
external cellular signaling to regulate cell adhesion, migration,
mitogenesis, differentiation, and survival [13]. They also regulate
angiogenesis [13–15]. Previous studies suggested that Cyr61
induces cell proliferation, cell adhesion and angiogenesis through
activation of integrin (aVb3) in endothelial cells [16]. CTGF plays
a key role downstream of TGF-b and SMAD signaling and
stimulates production of fibronectin and collagen, which is
important for wound healing [17,18]. WISP-1 is strongly
expressed in the fibrovascular stroma of breast tumors developing
in Wnt-1 transgenic mice [10]. Forced overexpression of WISP-1
in normal rat kidney fibroblasts (NRK-49F) was sufficient to
induce their transformation [11]. Moreover, increasing evidence
has suggested that CCN proteins are involved in tumorigenesis,
and variation of expression of these molecules has been observed
in several types of cancers [8,9].
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We have demonstrated that Cyr61 acted as a tumor suppressor
in the growth of NSCLC cells. Cyr61 suppressed the growth of
NSCLC cells by triggering a signal transduction pathway through
upregulation of p53 [6,19]. CTGF and WISP-1 also affected the
tumorigenicity of lung cancer cells [5,20–22]. However, correla-
tions between the three molecules with clinical features of lung
cancer are unexplored. Our previous work suggested that expres-
sion of CCN family proteins has prognostic value for glioma
progression and overall patient survival [23]. In the present
studies, we performed real-time quantitative RT-PCR and
immunohistochemistry to measure the mRNA and protein levels
of three CCN genes in primary NSCLC samples and their
matched normal lung tissues. Furthermore, we determined
whether levels of these CCN genes were correlated with clinical
features of NSCLC samples by several statistical analysis models.
MATERIALS AND METHODS
Patients and samples
This study analyzed the primary cancer and matched normal
tissues from 60 NSCLC patients treated at the First Affiliated
Hospital of Zhengzhou University (Henan, China) from 2002 to
2005 after their written informed consent. Cancer samples were
resected surgically without any neo-adjuvant therapy and corre-
sponding non-cancerous tissues, which were at least 3–4 cm away
from cancer, were also obtained. Each specimen was divided into 2
parts: one was sectioned and examined histologically by traditional
H&E staining for the presence of more than 80% tumor cells (cancer
sample) or only normal cells without any inflammatory or tumor
infiltrating areas (matched normal sample); the other was frozen in
liquid nitrogen and stored at 280uC until analysis. Our work was
approved by the Institutional Review Board of the Institute for
Nutritional Sciences, Chinese Academy of Sciences.
RNA extraction and cDNA synthesis
Total RNA was extracted from fresh-frozen NSCLC specimens
and matched normal lung tissues by TRIzol reagent (Life
Technologies, Inc.) according to the manufacturer’s protocol.
The quality of the RNA samples was determined by electropho-
resis through agarose gels and staining with ethidium bromide, the
18S and 28S RNA bands were visualized under UV light. 2 mg of
total RNA was processed directly to cDNA by reverse transcrip-
tion with Superscript II (Life Technologies, Inc.) according to the
manufacturer’s protocol in a total volume of 50 ml.
Real-time reverse transcription PCR (RT-PCR)
RT-PCR was characterized at the point during cycling when
amplification of the PCR product was first detected, rather than
the amount of PCR product accumulated after a fixed number of
cycles. The parameter Ct was defined as the fractional cycle
number at which the fluorescence generated by passing a fixed
threshold above baseline. The level of target gene in unknown
samples was quantified by measuring the Ct value: Level(target) =
2Ct(target). The Ct value of b-actin was also measured as the
endogenous RNA control: Level(b-actin) = 2Ct(b-actin). The levels of
target genes in each sample were normalized on the basis of its
b-actin content through the formula: Normalized level (NL) =Le-
vel(target)/Level(b-actin) = 2Ct(target)/2Ct(b-actin) = 2Ct(target)-Ct(b-actin) =
2DCt. Furthermore, the relative levels (RL) of target genes in cancer
samples versus matched normal tissues were calculated accord-
ing to the formula: RL=NL(cancer)/NL(normal) = 2DCt(cancer)/
2DCt(normal) = 2[DCt(cancer)2DCt(normal)] = 2DDCt. Because both NL
and RL are represented as 2Ct, we therefore used DCt and DDCt
as NL and RL, respectively, for clinical statistical analysis.
Primers for real-time PCR for Cyr61 (59-GAGTGGGTCTGT-
GACGAGGAT-39 and 59-GGTTGTATAGGATGCGAGGCT-
39), CTGF (59-CGACTGGAAGACACGT TTGG-39 and 59-
AGGCTTGGAGATTTTGGGAG-39), WISP-1 (59-AGAGCC-
GC CTCTGCAACTT-39 and 59-GGAGAAGCCAAGCCCA-
TCA-39) and b-actin (59-G ATCATTGCTCCTCCTGAGC-39
and 59-ACTCCTGCTTGCTGATCCAC-39) were designed using
software PRIMER3 and purchased from Shanghai Sangon Biolo-
gical Engineering Technology & Services CO., Ltd. Amplification
reactions were performed in a 20 ml volume of the LightCycler-
DNA Master SYBR Green I mix (Roche Diagnostics Ltd., Applied
Science, Penzberg, Germany) with 10 pmol of each primer, MgCl2
concentration optimized between 2 and 5 mM, 200 mM of each
dNTP, 0.5 U Taq DNA polymerase, and 16buffer. All of the
reactions were performed in triplicate in an iCycler iQ system (Bio-
Rad, Hercules, CA), and initial denaturation at 95uC for 3 min was
followed by 40 cycles of a denaturation at 95uC for 30 s, an
annealing step between 55uC and 58uC for 20 s, and an extension
step at 72uC for 30 s. A final extension step at 72uC for 7 min was
added. To confirm specificity of amplification, the PCR products
from each primer pair were subjected to a melting curve analysis and
subsequent inspection after agarose gel electrophoresis.
Statistical analysis
T-test and ANOVA were adopted to study the expression of 60
pairs of NSCLC and normal lung tissues for each CCN gene and
their association with single clinical factors (family history,
metastasis, smoking, tumor stage, histology, tuberculosis, gender,
tumor size and patient’s age). Pearson’s correlation analysis was
used to estimate relative degree by quantity of the expression of the
three genes. Pearson’s correlation reflects the degree of linear
relationship between two variables. It ranges from +1 to 21. The
relative values (tumor/control) were relative to actin plotted. For
each gene, Kaplan-Meier survival curves for patients with high
gene expression versus low gene expression were plotted and log-
rank test was used for comparing the equality of the two survival
curves. Multivariable analyses with the Cox proportional hazards
model were used to estimate the effects of the clinical character-
istics and the expression of the three genes on survival. Results
were considered significant at P,0.05 or highly significant at
P,0.01. All statistical analyses were performed using the program
SPSS for Windows (SPSS, Chicago, IL).
Immunohistochemistry
For immunohistochemistry, cancerous and corresponding normal
lung tissues were frozen in a cryostat chamber and 10 mm sections
were collected on glass slides. The sections were fixed in ice-cold
acetone for 30 min, washed in 0.01 M PBS for 365 min, blocked
for 1 hr in 0.01 M PBS supplemented with 0.3% Triton X-100 and
5% normal serum, and then incubated with rabbit anti-human
Cyr61 (polyclonal, 1:500; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), goat anti-human CTGF (polyclonal, 1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), or goat anti-human WISP-1
(polyclonal, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), respectively, at 4uC overnight. After brief washes in 0.01 M
PBS, sections were incubated for 2 hr in 0.01 M PBS with
horseradish peroxidase-conjugated goat anti-rabbit IgG or rabbit
anti-goat IgG (1:1000; Chemicon, Temecula, CA, USA), followed
by visualization with 0.003%H2O2 and 0.03%DAB in 0.05 MTris-
HCl (pH 7.6). Negative controls consisted of substitution of the
primary antibody with normal serum at the same dilution.
Immunohistochemistry for each individual was performed at least
3 times and all sections were counterstained with hematoxylin.
CCN Expression in Lung Cancers
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Scoring of immunohistochemistry staining was carried out in-
dependently by three pathologist blinded to the patient’s clinical
parameters. All stained sections were scored both in the tumor and
adjacent non-tumor areas at least in 10 high-power field areas with
a minimum of 300 preserved cells assessed in each area. The
percentage of cells expressing target protein was estimated by
dividing the number of positive cells by the number of total cells per
high-power field area. Lung epithelial cells bearing obvious brown
signal in the cytoplasm compared with negative control were defined
as positive cells. Paired-samples t-test was used to evaluate the
difference between protein levels of Cyr61, CTGF, or WISP-1 in
cancer samples compared with matched normal lung tissues. Results
were considered statistically highly significant at P,0.01. All
statistical analyses were performed using the program SPSS for
Windows (SPSS, Chicago, IL).
RESULTS
Expression of Cyr61, CTGF, and WISP-1 genes in
NSCLC and matched normal lung tissues
To study the expression pattern of CCN genes in NSCLC, levels
of Cyr61, CTGF, and WISP-1 mRNA were quantified in 60 pairs of
tumors and their matched normal lung tissues by real-time PCR.
Expression level was shown as a ratio between Cyr61, CTGF, or
WISP-1 and the reference gene b-actin to correct for the variation
in the amounts of RNA. Downregulation of Cyr61 and CTGF
mRNA occurred in 48 of 60 (80%) and 39 of 60 (65%) NSCLC
samples compared with the paired normal lung tissues, re-
spectively. In contrast, upregulation of levels of WISP-1 mRNA
was observed in 50 of 60 (83%) NSCLC samples in comparison
with their normal tissues (Fig. 1). Univariate analysis showed that
mRNA level of either Cyr61, CTGF, or WISP-1 genes were
significantly different between the cancer samples and paired
normal ones (Table 1). Expression of Cyr61 and CTGF in primary
lung cancers was significantly lower than in matched normal lung
tissues (P,0.001 and P= 0.016, respectively). In contrast, levels of
WISP-1 in cancers were significantly higher than those in the
matched normal ones (P,0.001) (Table 1). Pearson’s correlation
analysis further showed that expression of Cyr61 and CTGF was
highly positively correlated (R= 0.604; P,0.001), whereas expres-
sion of WISP-1 and CTGF showed a significant negative
association (R=20.299; P= 0.020). Expression of WISP-1 and
Cyr61 was not significantly correlated (R=20.182; P= 0.164)
(Table 2). Because the three genes are all members of CCN family,
Figure 1. Expression patterns of Cyr61, CTGF, and WISP-1 mRNAs in NSCLC and matched normal lung tissues. Relative mRNA expression levels of
Cyr61, CTGF, and WISP-1 are shown in 60 pairs of primary NSCLC tissues and matched normal lung samples. Expression is displayed as a ratio of
expression of CCN genes in cancer versus matched normal tissues. Each bar is the log2 value of the ratio of CCN expression levels between lung
tumors (T) and matched normal tissues (N) from the same patients. Less than 2-fold change: the ratio between tumor and normal is,2. Because Log2
2= 1, bar value .1 represents .2-fold increase (T.N), whereas bar value ,21 represents .2-fold decrease (T,N).
doi:10.1371/journal.pone.0000534.g001
CCN Expression in Lung Cancers
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it is possible that their expression might be controlled by some
common regulators (for Cyr61 and CTGF) or antagonized by each
other (for WISP-1 and CTGF).
Immunohistochemistry was used to monitor the protein
expression of Cyr61, CTGF, and WISP-1 in the 60 pairs of lung
tissues. Paired-samples t-test indicated that protein expression of
Cyr61 (P,0.001) and CTGF (P,0.001) was dramatically down-
regulated in cancer tissues compared with their normal counter-
parts (Figure 2). Additionally, significant upregulation of WISP-1
was found in the cancer samples (P,0.001) in comparison with
matched normal tissues (Figure 2). Representative photographs
showed that Cyr61 was highly expressed in the cytoplasm of lung
epithelial cells in the normal lung tissues of patients with lung
carcinoma (Fig. 3A), but levels were remarkably decreased in the
cancerous counterparts (Fig. 3B). Notably, the downregulation of
Cyr61 is mainly due to the large reduction of Cyr61 expression
level in individual cells rather than a decreased number of Cyr61-
positive lung epithelial cells. CTGF displayed higher intensity of
staining in the cytoplasm of normal lung epithelial cells (Fig. 3D)
than that in lung cancer cells (Fig. 3E); the ratio of CTGF-positive
to -negative cells in cancer tissues was clearly lower in comparison
with the corresponding normal lung tissues. Although expression
of WISP-1 was low in the cytoplasm of epithelial cells derived from
normal lung tissues (Fig. 3G), it was remarkably increased in
matched lung-cancer tissues (Fig. 3H). Taken together, the result
of immunohistochemistry paralleled those of real-time RT-PCR.
Table 1. Expression of Cyr61, CTGF, and WISP-1 mRNA in lung
cancer and matched normal lung tissues.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene N Cancer Matched-normal P{
Cyr61 60 2.7464.16{ 4.9363.34 0.001
CTGF 60 1.4063.53 2.4163.37 0.016
WISP-1 60 23.0963.53 25.8263.67 0.001
{Means 6 SD of expression of Cyr61, CTGF, and WISP-1 mRNA in lung cancer or
matched normal samples after normalized to b-actin in the same samples.
{P,0.05 and P,0.01 are set for significant and highly significant difference,
respectively.
doi:10.1371/journal.pone.0000534.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Table 2. Pearson’s correlation matrix of Cyr61, CTGF, and WISP-
1 mRNA in 60 pairs of samples.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variables Correlation (R) P{
Cyr61 and CTGF 0.604 0.001
Cyr61 and WISP-1 20.182 0.164
CTGF and WISP-1 20.299 0.020
{P,0.05 and P,0.01 are set for significant and highly significant difference,
respectively.
doi:10.1371/journal.pone.0000534.t002..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Figure 2. Expression patterns of Cyr61, CTGF,
and WISP-1 protein in NSCLC and matched
normal lung tissues. The graph depict distribu-
tions of specimens according to the percentage of
cells positive for Cyr61, CTGF, and WISP-1 in 60
pairs of NSCLC and matched non-cancerous lung
tissues. P values (paired-samples t-test) are listed
suggesting the difference between NSCLC samples
versus matched normal tissues.
doi:10.1371/journal.pone.0000534.g002
CCN Expression in Lung Cancers
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Relationship between expression of Cyr61 in lung
cancers and the clinical and pathological features of
the individuals
Univariate analysis proved that a significant association existed
between expression of Cyr61 versus tumor stage, metastasis,
histological subtype, smoking and family history (Table 3). Level
of Cyr61 expression was decreased significantly in high stage
tumors compared to low stage tumors (P = 0.014). Multiple
comparison (LSD t-test) analysis showed that expression of Cyr61
between tumors of stages I and III were significantly different
(P = 0.004); but no significant difference in Cyr61 expression
occurred in NSCLC samples comparing either stages I and II
(P = 0.063) or stages II and III (P = 0.17). Histological analysis
showed that a significant difference existed among SC, AC, adeno-
squamous cell carcinoma (ASC) and other pathological type in
level of expression of Cyr61 (P = 0.001). Moreover, multiple
comparison (LSD t-test) demonstrated that expression of Cyr61
between SC versus ASC (P= 0.009) or SC versus other pathological
type (P= 0.001) was significantly different. Similarly, significant
differences of Cyr61 expression were also observed between AC
versus ASC (P= 0.015) or AC versus other pathological type
(P = 0.002). Smoking was associated with low expression of Cyr61
(P = 0.009). In contrast, expression of Cyr61 was not correlated
with tuberculosis, gender, age, and tumor size (Table 3).
Relationship between expression of CTGF in lung
cancers and the clinical and pathological features of
the individuals
Statistical analysis revealed that expression of CTGF was strongly
associated with some clinical features of NSCLC, including tumor
stage, metastasis, histology, smoking, and family history (Table 3).
Level of CTGF was decreased significantly in high-stage tumors
compared to low-stage tumors (P = 0.040). Moreover, significant
difference of CTGF expression existed between tumors, stage I
versus stage III (P = 0.013) and stage II versus stage III (P = 0.024);
however, no significant statistical difference was observed between
tumors, stage I and II (P = 0.077). For metastasis, the expression of
CTGF in metastatic NSCLC was significantly lower than in non-
metastatic NSCLC (P=0.039); significantly, smoking was associated
with a prominent suppression of CTGF expression in NSCLC
(P=0.017) (Table 3). Additionally, a significant difference occurred
among SC, AC, ASC and other pathological types in the level of
CTGF (P=0.005). In addition, level of CTGF in the patients was
significantly lower than those whose family members did not have
cancer (P=0.038). However, gender, tumor size, age and histology
of tuberculosis showed no significant correlations with the expression
of CTGF (Table 3).
Relationship between expression of WISP-1 in
NSCLC and the clinical and pathological features of
the individuals
Statistical analysis showed that expression of WISP-1 was
significantly associated with tumor histology, as well as age of
NSCLC patients at diagnosis (Table 3). One-way ANOVA
analysis demonstrated that significant differences existed among
SC, AC, ASC and other histological type in their expression of
WISP-1 (P = 0.017). Level of WISP-1 in ASC was much higher
than those in either SC (P= 0.002) or AC (P= 0.015). Moreover,
younger patients (ages, 35–50) had a significantly higher level of
WISP-1 in their tumors than older individuals (ages, 50–65 or
$65) (P = 0.018 and P= 0.036, respectively). In contrast, other
clinical parameters (family history, metastasis, history of smoking,
tuberculosis, gender, tumor type, and tumor size) were not
associated with expression of WISP-1.
Expression of Cyr61, CTGF, WISP-1 genes and clinical
outcome of NSCLC
Univariate survival analysis showed that the expression of Cyr61,
CTGF, metastasis, and smoking were significantly associated with
survival (Table 4). Kaplan-Meier curves suggested that patients
with the high-expression of Cyr61 showed a significantly extended
mean survival time in comparison with the other patients (Fig. 4A)
(P = 0.001). Similarly, high levels of CTGF were associated with
prolonged survival (Fig. 4B) (P = 0.031). In contrast, no significant
association of WISP-1 expression and survival was noted (Fig. 4C)
(P = 0.214). After controlling the clinical and pathological
characteristics (age, gender, metastasis, smoke, tumor stage,
tuberculosis, tumor size), multivariate (Cox regression) survival
analysis was conducted to evaluate the potential effects of the three
CCN genes on cancer prognosis. The result showed that both
Cyr61 and CTGF were significantly independent positive prognos-
tic factors for survival of patients with NSCLC, and the relative
risk was 0.047 for Cyr61 and 0.0357 for CTGF (Table 5). However,
no significant association occurred between WISP-1 expression
and survival (Table 5).
Figure 3. Representative immunohistochemistry result, staining for
Cyr61, CTGF, and WISP-1 in NSCLC and matched normal lung tissues.
In non-cancerous lung tissues from patients with NSCLC, intense Cyr61
immunoreactivity (brown) is observed in the cytoplasm of cells as well
as extracellular space (A). In corresponding NSCLC tissues, Cyr61
immunoreactivity is less (B) compared with normal lung tissue. Similar
to Cyr61, many CTGF-positive cells (brown) are visible in non-tumor
lung tissues (D), and positive signals are only sparsely distributed in
NSCLC tissues (E). WISP-1 immunohistochemistry, however, displays
a different expression pattern. WISP-1 immunoreactivity (brown) is
barely detected in normal lung tissues from NSCLC patients (G) but is
markedly increased in NSCLC tissues (H). C, F, and I are negative
controls of Cyr61, CTGF, and WISP-1, respectively. All slides are
counterstained with hematoxylin (blue). Scale bar = 60 mm.
doi:10.1371/journal.pone.0000534.g003
CCN Expression in Lung Cancers
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DISCUSSION
Cyr61, CTGF, and WISP-1 play important roles in cell prolifera-
tion, migration and differentiation. Their expression appears to be
regulated differently in various types of tumors. To explore the
correlation between expression of CCN genes and NSCLC, we
used real-time PCR and immunohistochemistry to evaluate the
mRNA and protein levels of these three genes in NSCLC and their
matched normal lung tissues. Downregulation of Cyr61 and CTGF
and upregulation of WISP-1 occurred in the NSCLC samples
compared to their normal counterparts, suggesting that these
molecules might be associated with tumor formation and
progression in NSCLC.
Cyr61 is the first cloned member of the CCN family and its
regulatory roles in tumor cells have been widely reported in many
types of cancers. In breast cancers, Cyr61 is overexpressed and can
stimulate tumor progression [24–27]. A gastric adenocarcinoma
cell line became more tumorigenic when the cells were genetically
engineered to express high levels of Cyr61 [16]. Expression of
Cyr61 was high in rhabdomyosarcomas and cell lines derived from
malignant melanomas, colon adenocarcinomas, and bladder
papillomas [16,28]. Malignant gliomas often have high levels of
Cyr61 associated enhanced tumorigenicity mediated through the
integrin-linked kinase signaling pathway [29]. Upregulation of
Cyr61 expression was recently identified in peritoneal metastases
Table 3. Relationship between levels of Cyr61, CTGF, and WISP-1 mRNA in lung cancer and the clinical and pathological features of
these individuals.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Factors N Cyr61 CTGF WISP-1
Mean6SD* P** Mean6SD P value Mean6SD P
Family history{ 0.027 0.038* 0.767
No 48 21.7263.30 2.6962.37 2.6862.99
Yes 12 24.0762.79 0.5963.20 2.9662.68
Metastasis 0.003 0.039* 0.408
No 29 20.9163.05 1.8163.00 3.0662.98
Yes 31 23.3963.15 0.1563.12 2.4362.87
Smoke 0.009 0.017* 0.610
No 23 20.7863.25 1.7663.08 2.4962.11
Yes 37 23.0663.09 20.2162.93 2.8963.33
Tumor stage 0.014 0.040* 0.969
I 17 20.6563.08 2.4862.55 2.6662.01
II 25 22.0363.28 0.6962.68 2.8463.45
III 18 23.8662.96 0.014 20.0963.87 0.040* 2.6562.97 0.969
Histology 0.001 0.005** 0.017
SC{ 25 23.3262.42 2.4962.16 1.8562.74
AC1 15 23.3563.65 0.7862.57 2.3962.52
ASC" 10 20.3163.36 20.1764.57 5.1963.47
Other$ 10 0.4962.63 21.1962.88 3.0162.12
Tuberculosis 0.719 0.324 0.299
No 51 22.1363.50 1.1863.14 2.5762.94
Yes 9 22.5662.16 0.0563.22 3.6762.74
Gender 0.729 0.849 0.358
Male 45 22.2863.55 0.9663.41 2.9363.19
Female 15 21.9362.59 1.1462.29 2.1361.79
Tumor size 0.988 0.994 0.141
#100 cm3 26 22.0963.79 1.0863.53 2.5362.78
100 cm3– 10 22.5164.16 0.8762.88 4.0263.63
200 cm3– 8 22.0361.83 0.7862.55 0.9461.82
$300 cm3 16 22.2462.72 1.1063.19 3.1662.82
Age 0.089 0.801 0.047
35– 11 21.2964.01 1.1663.47 4.6863.85
50– 34 23.0163.00 1.1362.95 2.3062.63
$65 15 21.0063.15 0.4363.53 2.2962.29
{All patients included in this study were asked whether their living or dead first-degree relatives (parents, siblings, children) had been affected by a lung malignancy.
{squamous-cell carcinoma; 1adenocarcinoma; "adenosquamous-cell carcinoma; $including other pathological types except for squamous-cell carcinoma,
adenocarcinoma, adeno-squamous cell carcinoma.
*The value is the relative levels of normalized target genes by b-actin in cancer versus matched normal samples.
**P,0.05 and P,0.01 are set for significant and highly significant difference, respectively.
doi:10.1371/journal.pone.0000534.t003..
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from human pancreatic cancer [30]. Paradoxically, Cyr61 appears
to have the opposite role in lung cancer. We have reported that
Cyr61 was downregulated in four of 5 samples of lung cancer, and
lung cancer cells stably transfected with a Cyr61 expression vector
were less tumorigenic than the vector alone transfected control
cells [19]. Our further studies showed that forced expression of
Figure 4. Survival curves from the time of diagnosis for NSCLC
patients with either high (+) or low (2) expression of Cyr61 (A), CTGF
(B), and WISP-1 (C).
doi:10.1371/journal.pone.0000534.g004
Table 4. Univariate survival analysis of expression of Cyr61,
CTGF and WISP-1 mRNA in lung cancer and the clinical and
pathological of these individuals.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Factors N Events
Mean Survival
(Months) SE P{
Gender 0.4012
Male 45 15 8.5280 0.5314
Female 15 5 15.1274 0.5635
Age(year) 0.0598
#59 31 7 15.8039 0.7233
.59 29 13 11.4247 0.4792
Metastasis 0.0001
No 29 2 15.8548 0.3963
Yes 31 18 12.2135 0.8556
Family history{ 0.6451
No 48 17 14.9562 0.5524
Yes 12 3 6.6275 0.6240
Smoke 0.0387
No 23 10 12.6333 0.9882
Yes 37 10 15.5517 0.5926
Tumor stage 0.4774
I 17 0 Not reached Not
reached
II 25 13 13.7476 0.6353
III 18 5 9.1541 0.1925
Tuberculosis 0.7314
No 51 17 14.7840 0.6068
Yes 9 3 11.2774 0.8807
Tumor size 0.3670
#100 cm3 26 0 Not reached Not
reached
100 cm3 10 13 13.7517 0.6107
200 cm3 8 3 15.5655 1.4845
$300 cm3 16 4 8.9278 0.8053
Cyr61 0.0001
Low expression 27 18 9.6648 0.2857
High expression 33 2 11.9306 0.8388
CTGF 0.0313
Low expression 29 13 12.4020 0.3870
High expression 31 7 13.6814 0.9023
WISP-1 0.4008
Low expression 30 12 13.6041 0.6590
High expression 30 8 15.0882 0.8590
{All patients included in this study were asked whether their living or dead first-
degree relatives (parents, siblings, children) had been affected by a lung
malignancy.
{P,0.05 and P,0.01 are set for significant and highly significant difference,
respectively.
doi:10.1371/journal.pone.0000534.t004..
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Table 5. Cox regression analysis of Cyr61, CTGF, and WISP-1
mRNA in lung cancer.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene N RR 95%CI{ P{
Cyr61 60 0.047 0.010–0.216 0.0001
CTGF 60 0.357 0.137–0.933 0.0356
WISP-1 60 1.597 0.537–4.748 0.4000
{CI: confidence interval
{P,0.05 and P,0.01 are set for significant and highly significant difference,
respectively.
doi:10.1371/journal.pone.0000534.t005..
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Cyr61 in lung cancer cells resulted in their cell-cycle arrest in G1
phase mediated by p53 [6]. Here, we found that expression of
Cyr61 is decreased in NSCLC samples compared to their matched
controls, which strongly supports our former hypothesis. Cyr61
was also reported to inhibit growth of prostate cancer [31],
endometrial cancer [32] and leiomyomas [33]. Taken together,
the data suggested that Cyr61 might behave as a tumor suppressor
under certain circumstances in several tissue types, including
NSCLC.
CTGF was identified as a mitogen found in the conditioned
medium of human umbilical vein endothelial cells [34]. It encodes
a protein of 349 amino acids with 43% sequence identity to Cyr61,
and all 38 cysteines in CTGF and Cyr61 are completely
conserved. CTGF was found to be overexpressed in mammary
tumors [26,35], melanomas [36], pancreatic cancers [37],
sarcomas including chondrosarcomas [38,39]; while an inverse
correlation has been reported between the malignant phenotype
and the level of CTGF expression in fibroblasts and endothelial
cell tumors [40]. In our experiments, we found that the level of
expression of CTGF in NSCLCs was lower than in the matched
normal lung samples, implying its potential tumor-suppressing
function. Consistent with our finding, a recent study by Chien et al.
[20] showed that CTGF suppressed lung cancer cell growth by
induction of p53, as well as, by inhibition of insulin-like growth
factor-I dependent Akt phosphorylation and epidermal growth
factor-dependent extracellular signal-regulated kinase 1/2 phos-
phorylation.
On the other hand, we found that WISP-1 was overexpressed in
NSCLC samples compared to their normal lung tissue counter-
parts, suggesting that WISP-1 might act as an oncoprotein in
NSCLC. WISP-1 was identified as a gene that was upregulated in
Wnt-1 transformed C57 MG mouse mammary epithelial cells; it
has complete conservation of all 38 cysteine residues with those of
Cyr61 and CTGF [10]. WISP-1 has been associated with either
enhancing or inhibiting growth of tumors. For example, it is
strongly expressed in human breast and colon cancers [10]. Forced
overexpression of WISP-1 in normal rat kidney fibroblasts (NRK-
49F) was sufficient to induce their transformation [11]. In contrast,
WISP-1 expression was inversely correlated with proliferation,
metastasis and growth of melanoma cells [41,42]. Additionally,
our result that upregulation of WISP-1 was positively correlated
with lung cancer metastasis was consistent with findings from
a mouse model [21]. Paradoxically, Soon et al. found that in vitro
overexpression of WISP-1 decreased motility of lung cancer cells
[22]. Since WISP-1 is a secreted protein and functions mainly by
interaction with ECM, the difference in findings might reflect the
difference in ECM in vivo and in vitro.
Univariate statistical analysis further disclosed that low levels of
either Cyr61 or CTGF were related with the progression of
NSCLC, and the downregulation of Cyr61 and CTGF was more
notable in patients with family history than those without family
history. These data implied that Cyr61 and CTGF might be
tumor suppressor genes in lung cancer. Through multiple linear
regression analyses, moreover, we found that clinical features are
closely associated with levels of expression of Cyr61, CTGF and
WISP-1. Expression level of Cyr61 in 71% lung cancer samples was
determined by eight independent variables, mainly by AC, SC and
age. Levels of CTGF in NSCLCs were also markedly associated
with clinical features, but with some differences. Gender seemed to
play a role in expression of CTGF, but not Cyr61. Sex hormone
might regulate expression of CTGF, but more work is needed to
confirm this impression. Statistical analysis also revealed that levels
of these molecules were correlated with one another, suggesting
that their regulation may relate to similar signaling pathways.
Furthermore, levels of Cyr61, CTGF, and WISP-1 were tightly
related to pivotal clinical and prognostic features of NSCLC.
Perhaps, examining the levels of these three molecules either in the
primary tumor or in the malignant cells from sputa of patients may
help guide therapy.
In summary, our study examined the three CCN molecules
(Cyr61, CTGF, and WISP-1) and found correlations between their
levels and clinical features of NSCLCs. Although the detailed
mechanism remains to be investigated, our results might provide
new parameters for diagnosis and prognosis of NSCLC.
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